Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30134% above fair value
$25.97−0.45 (-1.70%)
Close on Nov 17, 2026Market cap $996.68MP/E –Yield –
Ceribell revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ceribell's revenue for the twelve months ending Jun 30, 2026 was $101.96M, up 31.7% year over year. For fiscal 2025 it was $89.06M, up 36.1% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.06M | +36.1% |
| FY2024 | Dec 31, 2024 | $65.44M | +44.7% |
| FY2023 | Dec 31, 2023 | $45.23M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.10M | +32.5% |
| Q1 FY2026 | Mar 31, 2026 | $26.49M | +29.3% |
| Q4 FY2025 | Dec 31, 2025 | $24.78M | +33.7% |
| Q3 FY2025 | Sep 30, 2025 | $22.59M | +31.4% |
| Q2 FY2025 | Jun 30, 2025 | $21.20M | +38.4% |
| Q1 FY2025 | Mar 31, 2025 | $20.49M | +42.3% |
| Q4 FY2024 | Dec 31, 2024 | $18.53M | +41.1% |
| Q3 FY2024 | Sep 30, 2024 | $17.20M | +48.1% |
| Q2 FY2024 | Jun 30, 2024 | $15.32M | – |
| Q1 FY2024 | Mar 31, 2024 | $14.40M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.13M | – |
| Q3 FY2023 | Sep 30, 2023 | $11.61M | – |
See a number that looks wrong?